SCHEMBL3245095

SCHEMBL3245095

CCCCCCCCCCCCCC(=O)N(C(=O)CCCCCCCCCCCCC)[C@@H](CCCCN)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 1/20 0.47
FFAR1 O14842 2/20 0.46
FFAR4 Q5NUL3 1/20 0.46
GRIK1 P39086 2/20 0.43
GRIK2 Q13002 2/20 0.43
GNAI3 P08754 1/20 0.42
GNAO1 P09471 1/20 0.42
GNAI1 P63096 1/20 0.42
GPR84 Q9NQS5 7/20 0.42
FAAH O00519 1/20 0.41
MAPT P10636 1/20 0.41
LCK P06239 1/20 0.41
PPARD Q03181 1/20 0.41
ZDHHC20 Q5W0Z9 1/20 0.41
ZDHHC2 Q9UIJ5 1/20 0.41
CPB2 Q96IY4 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
GSR P00390 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9716842 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL2345422 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL1532640 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL9716734 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL1532638 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL9314956 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL9716836 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL9716728 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL9716750 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2
SCHEMBL21838291 1.00 SLC6A5 (0.47) SLC6A5FFAR1FFAR4GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114651014-A IL-15 fusion peptides for the treatment of cancer 前列腺癌研究中心 2022-06-21 CN claimed
EP-4110809-A1 COMPOSITIONS AND METHODS King's College London (GB) 2023-01-04 EP disclosed
CN-114651014-A IL-15 fusion peptides for the treatment of cancer 前列腺癌研究中心 2022-06-21 CN disclosed
US-8647613-B2 Drug carrier JCR PHARMACEUTICALS CO., LTD. (JP) 2014-02-11 US disclosed
EP-1219659-B1 AMPHIPATHIC COMPOUND HAVING DENDRITIC STRUCTURE UNIV WASEDA (JP) 2010-07-28 EP disclosed
US-20090136443-A1 Drug Carrier OXGENIX CO., LTD. (JP) 2009-05-28 US disclosed
US-6933352-B2 Amphiphilic compounds having a dendritic branch structure JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2005-08-23 US disclosed
US-20020120096-A1 Capable of stably fixing a water-soluble polymer onto a surface structure by taking advantage of intermolecular interaction, thereby enabling the water-soluble polymer to be carried thereon without giving any damage JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2002-08-29 US disclosed
EP-1219659-A1 AMPHIPATHIC COMPOUND HAVING DENDRITIC STRUCTURE Japan Science and Technology Corporation (JP) 2002-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136443-A1 Drug Carrier ABCB11, SLC47A1, SLC47A2 SLC6A5 504/4885FFAR1 360/4885FFAR4 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.